Heartflow (NASDAQ:HTFL) Stock: Insider Campbell Rogers Sells 16,918 Shares

Heartflow, Inc. (NASDAQ:HTFL – Get Free Report) insider Campbell Rogers sold 16,918 shares of the firm’s stock in a transaction that occurred on Wednesday, April 1st. The shares were sold at an average price of $24.67, for a total transaction of $417,367.06. Following the completion of the sale, the insider owned 83,511 shares of the company’s stock, valued at approximately $2,060,216.37. This trade represents a 16.85% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Campbell Rogers also recently made the following trade(s):

  • On Thursday, October 22nd, Campbell Rogers sold 12,157 shares of Heartflow stock. The stock was sold at an average price of $55.01, for a total value of $668,756.57.
  • On Friday, September 18th, Campbell Rogers sold 12,156 shares of Heartflow stock. The stock was sold at an average price of $50.15, for a total value of $609,623.40.
  • On Tuesday, November 17th, Campbell Rogers sold 12,157 shares of Heartflow stock. The shares were sold at an average price of $46.39, for a total transaction of $563,963.23.
  • On Tuesday, November 17th, Campbell Rogers sold 24,188 shares of Heartflow stock. The stock was sold at an average price of $46.39, for a total value of $1,122,081.32.
  • On Thursday, October 22nd, Campbell Rogers sold 23,933 shares of Heartflow stock. The shares were sold at an average price of $55.01, for a total transaction of $1,316,554.33.
  • On Friday, September 18th, Campbell Rogers sold 19,682 shares of Heartflow stock. The stock was sold at an average price of $50.15, for a total value of $987,052.30.

Heartflow Stock Performance

Heartflow stock opened at $46.69 on Friday. The stock’s 50 day simple moving average is $51.76 and its two-hundred day simple moving average is $35.64. Heartflow, Inc. has a 12 month low of $20.13 and a 12 month high of $60.65.

Heartflow (NASDAQ:HTFL – Get Free Report) last announced its quarterly earnings results on Thursday, November 12th. The company reported ($0.03) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.18) by $0.15. Heartflow had a negative net margin of 33.11% and a negative return on equity of 20.53%. The firm had revenue of $72.86 million for the quarter. During the same period last year, the company posted ($0.27) earnings per share. As a group, equities research analysts expect that Heartflow, Inc. will post -0.75 earnings per share for the current year.

More Heartflow News

These are some of the HTFL news items that stood out recently:

  • Positive Sentiment: A report headline says Heartflow’s Q2 revenue beat consensus and the company raised its full-year guidance—potentially signaling stronger growth expectations. The provided article text offers few details on the results. Article: HeartFlow Q2 revenue and guidance
  • Negative Sentiment: Recent coverage flagged insider share sales, including a transaction reported at about $4.2 million. Other reports describe Campbell Rogers’ sales, some made under pre-arranged Rule 10b5-1 plans. Insider selling can unsettle investors, although planned sales do not necessarily signal a change in the insider’s view of the company. Article: Heartflow insider sale
  • Negative Sentiment: Put-option trading rose sharply, with 6,628 puts traded—about 558% above the reported average. This may reflect increased demand for downside protection or bearish bets, though options activity alone does not establish investors’ outlook.

Analyst Ratings Changes

Several equities research analysts have commented on the company. Morgan Stanley boosted their price objective on Heartflow from $35.00 to $40.00 and gave the stock an “equal weight” rating in a research note on Friday, August 14th. JPMorgan Chase & Co. raised their target price on shares of Heartflow from $35.00 to $45.00 and gave the stock an “overweight” rating in a research note on Friday, August 14th. Robert W. Baird boosted their target price on Heartflow from $56.00 to $68.00 and gave the stock an “outperform” rating in a report on Friday, November 13th. Weiss Ratings restated a “sell (d-)” rating on shares of Heartflow in a research report on Wednesday, November 4th. Finally, Piper Sandler restated an “overweight” rating and issued a $64.00 price target (up from $45.00) on shares of Heartflow in a research report on Tuesday, October 20th. One research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $60.12.

Get Our Latest Stock Report on HTFL

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the company. XXEC Inc. purchased a new stake in shares of Heartflow in the second quarter valued at about $2,524,764,000. BlackRock Inc. acquired a new stake in Heartflow during the second quarter worth about $152,502,000. Bamco Inc. NY purchased a new position in Heartflow during the second quarter worth about $94,625,000. Jupiter Topco LLC purchased a new position in Heartflow during the second quarter worth about $70,983,000. Finally, Janus Henderson Group PLC boosted its holdings in Heartflow by 152.0% in the 1st quarter. Janus Henderson Group PLC now owns 2,180,976 shares of the company’s stock valued at $53,063,000 after purchasing an additional 1,315,416 shares during the last quarter.

Heartflow Company Profile

(Get Free Report)

HeartFlow, Inc. is a medical technology company that develops noninvasive tools to help clinicians assess coronary artery disease. Its platform analyzes coronary CT angiography scans to create personalized models of a patient’s coronary arteries and provide information that can support diagnosis and treatment planning. The company’s offerings include HeartFlow FFR CT Analysis, which estimates blood flow and the effects of artery narrowing, and tools for assessing coronary plaque. The technology combines medical imaging with computational analysis and artificial intelligence, giving clinicians information without requiring an invasive procedure to measure blood flow.

Read More

Insider Buying and Selling by Quarter for Heartflow (NASDAQ:HTFL)

Receive News & Ratings for Heartflow Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heartflow and related companies with MarketBeat.com's FREE daily email newsletter.